SeaStar Medical Holding Corporation

SeaStar Medical Holding Corporation is a commercial-stage medical device company focused on therapies for critically ill patients facing organ failure and severe inflammatory conditions. SeaStar Medical develops and commercializes extracorporeal treatment systems centered on its Selective Cytopheretic Device platform, which is designed to modulate harmful immune responses and reduce hyperinflammation. The company’s current product portfolio includes QUELIMMUNE, an FDA-approved treatment for pediatric acute kidney injury associated with sepsis or septic condition requiring renal replacement therapy, along with additional SCD-based programs in adult kidney injury and other serious inflammatory indications. Based in Denver, Colorado, SeaStar Medical operates in the medical technology and specialty devices market, addressing unmet needs in hospital intensive care and renal replacement settings.

Sector

Healthcare

Industry

Biotechnology

CEO

Mr. Eric Schlorff

Employees

18

Headquarters

Denver, CO, United States

Website

seastarmedical.com